News und Analysen

Believe it or not, we're nearly halfway through this decade. The healthcare sector could be in store for monumental changes over the next few years.

These changes should present great opportunities

Believe it or not, we're nearly halfway through this decade. The healthcare sector could be in store for monumental changes over the next few years.

These changes should present great opportunities

It's no secret why Pfizer (NYSE: PFE) stock has been struggling this year. Investors are worried about how well the company will be able to do in light of waning demand for its COVID-19 vaccine and

There are things that can affect and sink the stock prices of companies in most industries. One of them is a short-seller report. Axsome Therapeutics (NASDAQ: AXSM), a mid-cap biotech, was recently

The benchmark S&P 500 index is up an exciting 25.8% over the past year, but many of its components haven't participated in the gains. Nvidia and other members of the "Magnificent Seven" have been

The benchmark S&P 500 index is up an exciting 25.8% over the past year, but many of its components haven't participated in the gains. Nvidia and other members of the "Magnificent Seven" have been

The S&P 500 is soaring as this bull market roars on, but some stocks, even those that have rebounded in recent times, still are trading at much lower levels than in the past. In fact, two stocks

The S&P 500 is soaring as this bull market roars on, but some stocks, even those that have rebounded in recent times, still are trading at much lower levels than in the past. In fact, two stocks

When one player stumbles in a high-stakes competition, it's often to the glee of the other contenders. In mid-June, Pfizer's (NYSE: PFE) gene-therapy candidate to treat Duchenne muscular dystrophy

It's obvious why Pfizer (NYSE: PFE) is eager to produce a medicine like Wegovy, Novo Nordisk's (NYSE: NVO) smash-hit obesity therapy that's essentially a slightly different version of its type 2

It's obvious why Pfizer (NYSE: PFE) is eager to produce a medicine like Wegovy, Novo Nordisk's (NYSE: NVO) smash-hit obesity therapy that's essentially a slightly different version of its type 2

If you're looking to pump up your passive income stream, there are a handful of high-yield dividend stocks that deserve your attention. AbbVie (NYSE: ABBV), Ares Capital (NASDAQ: ARCC), and Realty

Vertex Pharmaceuticals (NASDAQ: VRTX) recently excited the medical community with clinical trial results from an experimental diabetes treatment it's developing. In a nutshell, it looks like a

Vertex Pharmaceuticals (NASDAQ: VRTX) recently excited the medical community with clinical trial results from an experimental diabetes treatment it's developing. In a nutshell, it looks like a

Vertex Pharmaceuticals (NASDAQ: VRTX) recently excited the medical community with clinical trial results from an experimental diabetes treatment it's developing. In a nutshell, it looks like a

Would you like to widen the stream of passive income you can expect each year? Managing rental property is an option, but most retirees find this method less passive than they would like it to be.

Would you like to widen the stream of passive income you can expect each year? Managing rental property is an option, but most retirees find this method less passive than they would like it to be.

Making a million dollars from a single stock sounds like it could be an unrealistic goal. But if you pick a good growth stock, which also pays a dividend, and hold on to it for the long haul, it's

Making a million dollars from a single stock sounds like it could be an unrealistic goal. But if you pick a good growth stock, which also pays a dividend, and hold on to it for the long haul, it's

Investors looking for high-yield dividend stocks to buy now should turn their attention toward the healthcare sector: Three relatively reliable drugmakers are trading near their 52-week lows.

Their

Investors looking for high-yield dividend stocks to buy now should turn their attention toward the healthcare sector: Three relatively reliable drugmakers are trading near their 52-week lows.

Their

Nearly everything is going right these days for Eli Lilly (NYSE: LLY). Sales and profits have been soaring. So has the share price, jumping more than 50% year to date after a 59% gain in 2023. Lilly